Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395205 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL16224559 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL3805159 | 0.90 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL4766170 | 0.90 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL22120434 | 0.89 | HSD17B10 (0.41) | HSD17B10HPGD | |
| SCHEMBL22128107 | 0.89 | HSD17B10 (0.41) | HSD17B10HPGD | |
| SCHEMBL31066400 | 0.82 | MAPK1 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL15797129 | 0.82 | MAPK1 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL30867786 | 0.82 | MAPK1 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL22820950 | 0.81 | NPC1 (0.38) | USP2SMN1; SMN2HSD17B10NR1H2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12606572-B2 | Substituted heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4724445-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260028357-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| EP-4565579-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | Theras, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024254334-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4373822-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117916238-A | Compositions and methods for inhibiting RAS | 瑟拉斯有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606572-B2 | Substituted heterocycles and uses thereof | KRAS, HRAS, MYC | USP2 3471/4885SMN1; SMN2 1611/4885HSD17B10 2162/4885 |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | USP2 673/4885SMN1; SMN2 2490/4885HSD17B10 2767/4885 |
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | USP2 1517/4885SMN1; SMN2 1405/4885HSD17B10 3903/4885 |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | USP2 673/4885SMN1; SMN2 2490/4885HSD17B10 2767/4885 |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | USP2 2112/4885SMN1; SMN2 2830/4885HSD17B10 1872/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | USP2 1068/4885SMN1; SMN2 654/4885HSD17B10 2660/4885 |
| US-20260028357-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | KRAS, HRAS, MYC | USP2 3471/4885SMN1; SMN2 1611/4885HSD17B10 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.